Table 3.
Microbiological procedures in patients with COVID-19 and suspected bacterial CAP empirically treated with ceftaroline.
| Variable | No. of Patients | % | 95% CI |
|---|---|---|---|
| Blood Cultures | |||
| Blood Cultures Collected | 83/165 | 50 | 43–58 |
| Collection before Ceftaroline Initiation | 56/83 | 67 | 57–67 |
| Positive Blood Cultures a | 1/83 | 1 | 0–6 |
| Respiratory Cultures | |||
| Respiratory Cultures Collected b | 13/165 | 8 | 4–13 |
| Collection before Ceftaroline Initiation | 5/13 | 38 | 17–66 |
| Positive Respiratory Tract Cultures c | 3/13 | 23 | 7–52 |
| Urinary Antigen for Streptococcus Pneumoniae | |||
| Urinary Antigen for Streptococcus Pneumoniae Collected | 140/165 | 85 | 79–90 |
| Collection before Ceftaroline Initiation | 92/140 | 66 | 58–73 |
| Positive Urinary Antigen for Streptococcus Pneumoniae | 1/140 | 1 | 0–4 |
CAP, community acquired pneumonia; CI, confidence intervals; COVID-19, coronavirus disease 2019. a Only pathogens possibly responsible for CAP were considered (e.g., positive blood cultures for coagulase-negative staphylococci were excluded): Escherichia coli (n = 1); b Bronchoalveolar lavage fluid culture (n = 11), tracheal aspirate culture (n = 1), not specified (n = 1); c Enterobacter aerogenes (n = 2), Pseudomonas aeruginosa (n = 1)